445 related articles for article (PubMed ID: 32004205)
1. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
[TBL] [Abstract][Full Text] [Related]
2. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
[TBL] [Abstract][Full Text] [Related]
3. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
[TBL] [Abstract][Full Text] [Related]
4. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
5. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis.
Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P
J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
8. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
[TBL] [Abstract][Full Text] [Related]
9. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.
Walensky RP; Jacobsen MM; Bekker LG; Parker RA; Wood R; Resch SC; Horstman NK; Freedberg KA; Paltiel AD
J Infect Dis; 2016 May; 213(10):1523-31. PubMed ID: 26681778
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
[TBL] [Abstract][Full Text] [Related]
12. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
[TBL] [Abstract][Full Text] [Related]
14. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
[TBL] [Abstract][Full Text] [Related]
15. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
[TBL] [Abstract][Full Text] [Related]
16. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
[TBL] [Abstract][Full Text] [Related]
17. Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa.
Vazquez L; Moll AP; Kacin A; Ndlovu NE; Shenoi SV
AIDS Patient Care STDS; 2019 May; 33(5):214-219. PubMed ID: 31067125
[TBL] [Abstract][Full Text] [Related]
18. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
[TBL] [Abstract][Full Text] [Related]
20. Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness.
Reitsema M; Hoek AJV; van der Loeff MS; Hoornenborg E; van Sighem A; Wallinga J; van Benthem B; Xiridou M
AIDS; 2020 Mar; 34(4):621-630. PubMed ID: 31895142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
